Rapid Target Binding and Cargo Release of Activatable Liposomes Bearing HER2 and FAP Single-Chain Antibody Fragments Reveal Potentials for Image-Guided Delivery to Tumors / Felista L Tansi, Ronny Rüger, Claudia Böhm, Frank Steiniger, Martin Raasch, Alexander S Mosig, Roland E Kontermann, Ulf K Teichgräber, Alfred Fahr, Ingrid Hilger
Abstract: Liposomes represent suitable tools for the diagnosis and treatment of a variety of diseases, including cancers. To study the role of the human epidermal growth factor receptor 2 (HER2) as target in cancer imaging and image-guided deliveries, liposomes were encapsulated with an intrinsically quenched concentration of a near-infrared fluorescent dye in their aqueous interior. This resulted in quenched liposomes (termed LipQ), that were fluorescent exclusively upon degradation, dye release, and activation. The liposomes carried an always-on green fluorescent phospholipid in the lipid layer to enable tracking of intact liposomes. Additionally, they were functionalized with single-chain antibody fragments directed to fibroblast activation protein (FAP), a marker of stromal fibroblasts of most epithelial cancers, and to HER2, whose overexpression in 20-30% of all breast cancers and many other cancer types is associated with a poor treatment outcome and relapse. We show that both monospecific (HER2-IL) and bispecific (Bi-FAP/HER2-IL) formulations are quenched and undergo HER2-dependent rapid uptake and cargo release in cultured target cells and tumor models in mice. Thereby, tumor fluorescence was retained in whole-body NIRF imaging for 32-48 h post-injection. Opposed to cell culture studies, Bi-FAP/HER2-IL-based live confocal microscopy of a high HER2-expressing tumor revealed nuclear delivery of the encapsulated dye. Thus, the liposomes have potentials for image-guided nuclear delivery of therapeutics, and also for intraoperative delineation of tumors, metastasis, and tumor margins.Keywords: HER2; fluorescence quenching; liposomes; molecular targeting; optical imaging; tumor heterogeneity; tumor microenvironment..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
Oct 15 2020 |
---|---|
Erschienen: |
Oct 15 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Pharmaceutics - (2020,10) Artikel-Nummer 972, 21 Seiten |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tansi, Felista Lemnyui, 1974- [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Umfang: |
8 Illustrationen (farbig) |
---|
doi: |
10.3390/pharmaceutics12100972 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
1736702386 |
---|
LEADER | 01000naa a2200265 4500 | ||
---|---|---|---|
001 | 1736702386 | ||
003 | DE-627 | ||
005 | 20201027160836.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201027s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/pharmaceutics12100972 |2 doi | |
035 | |a (DE-627)1736702386 | ||
035 | |a (DE-599)KXP1736702386 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Tansi, Felista Lemnyui |d 1974- |e verfasserin |0 (DE-588)143697137 |0 (DE-627)653856679 |0 (DE-576)338437029 |4 aut | |
245 | 1 | 0 | |a Rapid Target Binding and Cargo Release of Activatable Liposomes Bearing HER2 and FAP Single-Chain Antibody Fragments Reveal Potentials for Image-Guided Delivery to Tumors |c Felista L Tansi, Ronny Rüger, Claudia Böhm, Frank Steiniger, Martin Raasch, Alexander S Mosig, Roland E Kontermann, Ulf K Teichgräber, Alfred Fahr, Ingrid Hilger |
264 | 1 | |c Oct 15 | |
300 | |b 8 Illustrationen (farbig) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract: Liposomes represent suitable tools for the diagnosis and treatment of a variety of diseases, including cancers. To study the role of the human epidermal growth factor receptor 2 (HER2) as target in cancer imaging and image-guided deliveries, liposomes were encapsulated with an intrinsically quenched concentration of a near-infrared fluorescent dye in their aqueous interior. This resulted in quenched liposomes (termed LipQ), that were fluorescent exclusively upon degradation, dye release, and activation. The liposomes carried an always-on green fluorescent phospholipid in the lipid layer to enable tracking of intact liposomes. Additionally, they were functionalized with single-chain antibody fragments directed to fibroblast activation protein (FAP), a marker of stromal fibroblasts of most epithelial cancers, and to HER2, whose overexpression in 20-30% of all breast cancers and many other cancer types is associated with a poor treatment outcome and relapse. We show that both monospecific (HER2-IL) and bispecific (Bi-FAP/HER2-IL) formulations are quenched and undergo HER2-dependent rapid uptake and cargo release in cultured target cells and tumor models in mice. Thereby, tumor fluorescence was retained in whole-body NIRF imaging for 32-48 h post-injection. Opposed to cell culture studies, Bi-FAP/HER2-IL-based live confocal microscopy of a high HER2-expressing tumor revealed nuclear delivery of the encapsulated dye. Thus, the liposomes have potentials for image-guided nuclear delivery of therapeutics, and also for intraoperative delineation of tumors, metastasis, and tumor margins.Keywords: HER2; fluorescence quenching; liposomes; molecular targeting; optical imaging; tumor heterogeneity; tumor microenvironment. | ||
700 | 1 | |a Rüger, Ronny |d 1979- |e verfasserin |0 (DE-588)136643612 |0 (DE-627)694539945 |0 (DE-576)301184313 |4 aut | |
700 | 1 | |a Böhm, Claudia |e verfasserin |4 aut | |
700 | 1 | |a Steiniger, Frank |d 1971- |e verfasserin |0 (DE-588)1220324698 |0 (DE-627)1736703862 |4 aut | |
700 | 1 | |a Raasch, Martin |d 1938-2008 |e verfasserin |0 (DE-588)1111918228 |0 (DE-627)865972532 |0 (DE-576)476333466 |4 aut | |
700 | 1 | |a Mosig, Alexander S. |e verfasserin |0 (DE-588)1131810422 |0 (DE-627)886552230 |0 (DE-576)488501571 |4 aut | |
700 | 1 | |a Kontermann, Roland |d 1961- |e verfasserin |0 (DE-588)122492609 |0 (DE-627)081976909 |0 (DE-576)169918793 |4 aut | |
700 | 1 | |a Teichgräber, Ulf |d 1970- |e verfasserin |0 (DE-588)115466711 |0 (DE-627)07726990X |0 (DE-576)289899532 |4 aut | |
700 | 1 | |a Fahr, Alfred |d 1949- |e verfasserin |0 (DE-588)140960317 |0 (DE-627)623798255 |0 (DE-576)321545508 |4 aut | |
700 | 1 | |a Hilger, Ingrid |d 1963- |e verfasserin |0 (DE-588)115770402 |0 (DE-627)077459415 |0 (DE-576)290066484 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d Basel : MDPI, 2009 |g (2020,10) Artikel-Nummer 972, 21 Seiten |h Online-Ressource |w (DE-627)614096529 |w (DE-600)2527217-2 |w (DE-576)313958653 |x 1999-4923 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2020 |
856 | 4 | 0 | |u https://doi.org/10.3390/pharmaceutics12100972 |x Verlag |z kostenfrei |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_31 | ||
912 | |a ISIL_DE-27 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
912 | |a GBV_ILN_2403 | ||
912 | |a GBV_ILN_2403 | ||
912 | |a ISIL_DE-LFER | ||
936 | u | w | |d 12 |j 2020 |y (2020,10) Artikel-Nummer 972, 21 Seiten |
951 | |a AR | ||
952 | |d 12 |j 2020 |y (2020,10) Artikel-Nummer 972, 21 Seiten | ||
980 | |2 31 |1 01 |x 0027 |b 3786847932 |y x |z 27-10-20 | ||
980 | |2 2403 |1 01 |x DE-LFER |b 380321677X |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 13-11-20 | ||
981 | |2 31 |1 01 |x 0027 |r https://doi.org/10.3390/pharmaceutics12100972 | ||
981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.3390/pharmaceutics12100972 | ||
982 | |2 31 |1 00 |x DE-27 |8 00 |a Universitätsbibliographie Jena | ||
982 | |2 31 |1 00 |x DE-27 |8 01 |a Medizinische Fakultät | ||
982 | |2 31 |1 01 |x 0027 |8 00 |a Friedrich-Schiller-Universität Jena | ||
982 | |2 31 |1 01 |x 0027 |8 00 |a OA-Förderung |